

AstraZeneca is pleased to announce that IMJUDO® (tremelimumab-actl) has been assigned a unique Healthcare Common Procedure Coding System (HCPCS) code and Average Sales Price (ASP) by the Centers for Medicare & Medicaid Services (CMS).

Effective for dates of services on or after July 1, 2023, the following code can be used by providers to identify IMJUDO when billing across settings of care as noted in the (2023) Alpha-Numeric HCPCS File available at: <https://www.cms.gov/files/document/2021-q4-hcpcs-coding-cycle.pdf>

Code	Description	Vial Size	Billing Units	NDCs
J9347	Injection, tremelimumab-actl, 1 mg	25 mg/1.25 mL single-dose vial	25 units	00310-4505-25
		300 mg/15 mL single-dose vial	300 units	00310-4535-30

NDC, National Drug Code

Effective with the January 2023 ASP Pricing File, CMS has also published an ASP associated with J9347. The most current ASP Pricing File can be referenced each quarter by following the link below:

<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice>

Each provider is responsible for ensuring all coding is accurate and documented in the medical record, based on the condition of the patient. The use of this information does not guarantee reimbursement. Healthcare providers are encouraged to contact payers to confirm code adoption and approved usage prior to submitting claims.

AstraZeneca Access 360™ can help with questions you may have about coding and reimbursement. For additional assistance, please contact Access 360 at 1-844-ASK-A360 (1-811-275-2360), Monday through Friday from 8 AM to 6 PM Eastern Time, or visit www.MyAccess360.com.

Support Services for IMJUDO are available only when prescribed with IMFINZI® (durvalumab) for certain FDA-approved indications. IMJUDO is not prescribed as a monotherapy. Please refer to full Prescribing Information when prescribing IMFINZI and IMJUDO at <https://www.imfinzihcp.com/>.